The Readout Loud 387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
36 snips
Feb 5, 2026 
Jason Mast, STAT staff reporter who covered Vertex’s sickle cell therapy rollout, joins to explain why manufacturing and stem-cell collection hurdles have slowed access. He breaks down the technical and logistical bottlenecks and how they affect patients and commercial prospects. Short updates also touch on shifting GLP-1 market dynamics and recent regulatory roadblocks.
AI Snips
Chapters
Transcript
Episode notes
Divergent GLP-1 Financial Outlooks
- Novo Nordisk forecasted a sharper sales decline than expected while Eli Lilly projected strong growth driven by market share gains.
- Pricing pressure and direct-to-consumer strategies explain divergent outlooks for competing GLP-1 sellers.
Oral GLP-1 Launch Accelerates Market Shift
- Novo's oral GLP-1 pill had a very fast launch with 50,000 prescriptions in a week, largely via direct-to-consumer channels.
- Novo priced the pill below rivals to capture share, potentially limiting Eli Lilly's uptake.
Cash Pay Reveals High Demand
- Many patients buy GLP-1 pills cash-pay, showing strong out-of-pocket demand for obesity treatments.
- It's unclear whether direct-pay channels will expand treatment to previously untreated patients.